Conversely, different studies have described pro-tumoral effects when TLR pathways were activated in tumor cells, including TLR8 6, arguing against the systemic or local use of TLR8 synthetic agonist in cancer immunotherapy. This evidence concerns the gene TLR8 and cancer.